Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Clearmind Medicine (Nasdaq: CMND) has filed a new international patent application for treating eating disorders using a combination of 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA). The clinical-stage biotech company aims to address the complex factors associated with conditions like anorexia and bulimia.
The announcement highlights the significant global impact of eating disorders, which affect up to 70 million people worldwide. The prevalence has increased from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents. These disorders rank among the top ten leading causes of disability among young women and have one of the highest mortality rates among mental disorders.
Clearmind Medicine (Nasdaq: CMND) ha depositato una nuova domanda di brevetto internazionale per il trattamento dei disturbi alimentari mediante una combinazione di 3-Metilmetcatinone (3-MMC) e Palmitoiletanolamide (PEA). Questa società biotecnologica in fase clinica mira a intervenire sui complessi fattori associati a condizioni come anoressia e bulimia.
L'annuncio sottolinea il significativo impatto globale dei disturbi alimentari, che colpiscono fino a 70 milioni di persone nel mondo. La loro prevalenza è aumentata dal 3,4% al 7,8% tra il 2000 e il 2018, soprattutto tra bambini e adolescenti. Questi disturbi sono tra le prime dieci cause principali di disabilità nelle giovani donne e presentano uno dei tassi di mortalità più elevati tra i disturbi mentali.
Clearmind Medicine (Nasdaq: CMND) ha presentado una nueva solicitud de patente internacional para el tratamiento de trastornos alimentarios utilizando una combinación de 3-Metilmetcatinona (3-MMC) y Palmitoiletanolamida (PEA). La empresa biotecnológica en fase clínica busca abordar los factores complejos asociados con condiciones como la anorexia y la bulimia.
El anuncio destaca el impacto global significativo de los trastornos alimentarios, que afectan hasta a 70 millones de personas en todo el mundo. La prevalencia ha aumentado del 3,4% al 7,8% entre 2000 y 2018, especialmente entre niños y adolescentes. Estos trastornos se encuentran entre las diez principales causas de discapacidad en mujeres jóvenes y tienen una de las tasas de mortalidad más altas entre los trastornos mentales.
Clearmind Medicine(나스닥: CMND)는 3-메틸메스카티논(3-MMC)과 팔미토일에탄올아마이드(PEA)의 조합을 이용한 섭식장애 치료에 관한 새로운 국제 특허 출원을 제출했습니다. 임상 단계에 있는 이 바이오테크 회사는 거식증과 폭식증과 같은 복잡한 요인을 해결하는 것을 목표로 하고 있습니다.
이번 발표는 전 세계적으로 최대 7천만 명에 달하는 섭식장애 환자 수와 그 영향력을 강조합니다. 2000년부터 2018년 사이에 유병률이 3.4%에서 7.8%로 증가했으며, 특히 아동과 청소년 사이에서 두드러집니다. 이러한 장애는 젊은 여성들 사이에서 장애의 주요 10대 원인 중 하나이며 정신 질환 중에서도 가장 높은 사망률을 보입니다.
Clearmind Medicine (Nasdaq : CMND) a déposé une nouvelle demande de brevet international pour le traitement des troubles alimentaires utilisant une combinaison de 3-Méthylméthcathinone (3-MMC) et de Palmitoyléthanolamide (PEA). Cette entreprise biotechnologique en phase clinique vise à traiter les facteurs complexes associés à des conditions telles que l’anorexie et la boulimie.
L’annonce souligne l’impact mondial important des troubles alimentaires, qui touchent jusqu’à 70 millions de personnes dans le monde. La prévalence est passée de 3,4 % à 7,8 % entre 2000 et 2018, notamment chez les enfants et les adolescents. Ces troubles figurent parmi les dix principales causes d’incapacité chez les jeunes femmes et présentent l’un des taux de mortalité les plus élevés parmi les troubles mentaux.
Clearmind Medicine (Nasdaq: CMND) hat eine neue internationale Patentanmeldung für die Behandlung von Essstörungen mit einer Kombination aus 3-Methylmethcathinon (3-MMC) und Palmitoylethanolamid (PEA) eingereicht. Das biotechnologische Unternehmen in der klinischen Phase möchte die komplexen Faktoren angehen, die mit Erkrankungen wie Anorexie und Bulimie verbunden sind.
Die Ankündigung hebt die erhebliche globale Auswirkung von Essstörungen hervor, die weltweit bis zu 70 Millionen Menschen betreffen. Die Prävalenz ist zwischen 2000 und 2018 von 3,4 % auf 7,8 % gestiegen, insbesondere bei Kindern und Jugendlichen. Diese Störungen gehören zu den zehn führenden Ursachen für Behinderungen bei jungen Frauen und weisen eine der höchsten Sterblichkeitsraten unter psychischen Erkrankungen auf.
- Filed new international patent application for novel eating disorder treatment
- Addresses large market opportunity with 70 million people affected globally
- Targets growing health concern with prevalence doubled from 3.4% to 7.8% (2000-2018)
- Early-stage development with no proven clinical efficacy yet
- Will require significant time and resources for clinical trials and regulatory approval
Insights
Clearmind expands IP portfolio with patent application for novel eating disorder treatment, representing early-stage R&D with uncertain commercial timeline.
Clearmind Medicine has filed an international patent application for a proprietary combination therapy targeting eating disorders, specifically using 3-Methylmethcathinone (3-MMC) with Palmitoylethanolamide (PEA). This filing represents an expansion of the company's intellectual property portfolio in the psychedelic-derived therapeutics space.
The target market is substantial - the article notes that up to 70 million people globally are affected by eating disorders, with prevalence increasing from
This patent application is part of Clearmind's broader strategy to develop novel treatments for undertreated mental health conditions. However, it's important to understand this represents very early-stage research and development. Patent applications are just one step in what's typically a lengthy process for novel therapeutics.
The filing contains no mention of preclinical or clinical data supporting the efficacy of this specific combination for eating disorders. There's also no information about the regulatory pathway or development timeline. For context, new therapeutics typically require years of preclinical testing, multiple phases of clinical trials, and regulatory review before commercialization.
For a clinical-stage biotech company like Clearmind, building a robust patent portfolio is a standard strategic move to protect potential future revenue streams. This application aligns with their stated focus on psychedelic-derived therapeutics, but represents continuation of existing strategy rather than a fundamental shift or breakthrough.
Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.
Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from
"The filing of this patent application underscores our continued commitment to developing innovative treatments for under-addressed mental health conditions," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. "By exploring the therapeutic potential of 3-MMC and PEA, we hope to provide new treatment options for individuals struggling with eating disorders." Clearmind's research and development efforts continue to focus on the potential of psychedelic-derived compounds to address a range of mental health challenges. The Company remains dedicated to advancing its pipeline of novel therapeutics through rigorous scientific investigation and clinical development.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to developing innovative treatments for under-addressed mental health conditions, its aim to provide new hope for individuals struggling with eating disorders, the potential of psychedelic-derived compounds to address a range of mental health challenges and advancing its pipeline of novel therapeutics through rigorous scientific investigation and clinical development. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new treatment method proposed by Clearmind Medicine (CMND) for eating disorders?
How many people are affected by eating disorders according to Clearmind's (CMND) announcement?
What is the significance of eating disorders in terms of disability and mortality?
What is the current development stage of Clearmind Medicine's (CMND) eating disorder treatment?
